Evaluating Insider Trading And Ownership For AcelRx Pharmaceuticals, Inc. (ACRX)


The Average True Range is an investor tool used to measure stock volatility.

ACRX has been the subject of a number of other research reports. (ACRX). These ratios are important while doing valuation of the company or the shares of the company. A break-up at the top trend line at $5.53 will firstly indicate a stronger raising rate. AcelRx Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Development Officer Hamel Lawrence G has sold 10,161 shares of AcelRx Pharmaceuticals, Inc. Jefferies Group LLC restated a "buy" rating and set a $7.00 target price on shares of AcelRx Pharmaceuticals in a report on Friday, July 14th.

Analysts have a mean recommendation of 2.40 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).

Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) had a decrease of 13.86% in short interest.

Shares plunged 59.81% to US$2.15 each in United States pre-market trading. The market capitalization of the company is at $251.18 Million.

The stock of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) hit a new 52-week high and has $2.36 target or 5.00 % above today's $2.25 share price.

According to Amgen Inc.'s Insider ownership is at 0.20%.

In the last earnings report the EPS was $-1.10 and is projected to be $-1.13 for the current year with 45,380,000 shares outstanding.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has shown an EPS growth of 3.80% in the last 5 years and sales growth of 74.50% for the same year while for the next 5 years; the EPS growth estimates -.Along with this Sales growth yoy (quarter over quarter) was considered as -40.00%.

Apple teaming up with Spielberg to take on the world of television
According to The Wall Street Journal , each episode will have a budget of more than $5 million, ... Apple ( AAPL ) is serious about original content-a space that is getting increasingly crowded.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal.

CEO, Angotti Vincent J., purchased 15,000 common shares of AcelRx Pharmaceuticals, Inc.

Acelrx Pharmaceutica (ACRX)'s Williams Percent Range or 14 day Williams %R presently is at -92.00.

Session activity on MannKind Corporation (NASDAQ:MNKD) shares bumps the stock on today's most active list. Vincent J. Angotti, CEO bought $45,000 worth of shares at an average price of $3.00 on Thursday the 24th. Beta factor, which is used to measure risk associated with the stock, was 3.02. With an institutional ownership near 0%, it carries an earnings per share ratio of -0.93. The disclosure for this purchase can be found here. Creative Planning augmented its investment by buying 3,600 shares an increase of 25.5% in the quarter.

Multiple company employees have indulged in significant insider trading.

Several institutional investors and hedge funds have recently modified their holdings of the company. It turned negative, as 17 investors sold AcelRx Pharmaceuticals Inc shares while 15 reduced holdings. Short shares grew from 4,013,284 to 4,807,548 over that timeframe. Waters Parkerson & Ltd Liability Corp holds 3,860 shares or 0.02% of its portfolio.

EX-99.1 2 ex_96542.htm EXHIBIT 99.1 ex_96542.htm Exhibit 99.1 Press Release AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA REDWOOD CITY, ... Virtu KCG Holdings LLC lifted its holdings in shares of AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Finally, LMR Partners LLP purchased a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $319,000.

Analysts look for public financial statements, listen in on conference calls and talk to managers and customers of a company in order to reach an opinion and communicate the value of a stock.

AcelRx Pharmaceuticals is a specialty pharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain.